Stimulating glucagon secretion to prevent low blood sugar in Type 1 Diabetes
Targeting alpha-cell GPCRs to stimulate glucagon and counter hypoglycemia
This study is looking at how certain amino acids and a hormone can help boost the body's natural glucagon production to help people with Type 1 Diabetes avoid severe low blood sugar episodes, aiming to find a safer option than current glucagon treatments.
Quick facts
| Grant type | Career grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Duke University NIH-funded |
| Lab location | 1 site (Durham, United States) |
| Project ID | NIH-10894185 on NIH RePORTER |
What this research studies
This research investigates how to stimulate the body's own glucagon secretion to counteract severe hypoglycemia in individuals with Type 1 Diabetes (T1D). It focuses on the effects of amino acids, particularly alanine and arginine, and a hormone called glucose-dependent insulinotropic peptide (GIP) on glucagon release. By understanding how these substances work together to enhance glucagon secretion, the research aims to develop a safer alternative to exogenous glucagon treatments. The study will explore the physiological mechanisms behind glucagon release and how they may differ in T1D patients.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals with Type 1 Diabetes who experience episodes of hypoglycemia.
Not a fit: Patients without Type 1 Diabetes or those who do not experience hypoglycemia may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that help prevent dangerous low blood sugar episodes in people with Type 1 Diabetes.
How similar studies have performed: Previous research has shown promising results in stimulating glucagon secretion using similar approaches, indicating potential for success in this area.
Where this research is happening
Durham, United States
- Duke University — Durham, United States (Active)
Researchers
- Principal investigator: El, Kimberley M — Duke University
- Study coordinator: El, Kimberley M
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.